<DOC>
	<DOCNO>NCT00242515</DOCNO>
	<brief_summary>Primary Objectives : This pilot project determine feasibility preemptive CD8+ deplete T-cell donor lymphocyte infusion ( DLI ) : - Reducing incidence graft versus host disease ( GVHD ) base standard classification acute chronic GVHD - Improving hte disease remission rate comparison previous study result . Secondary Objectives : - To investigate impact CD8+ deplete T-cell DLI hematopoietic chimerism , immunologic recovery transplant patient .</brief_summary>
	<brief_title>T-cell Depleted Donor Lymphocyte Infusion ( DLI ) Acute Myeloid Leukemia ( AML ) High Risk Myelodysplastic Syndrome ( MDS )</brief_title>
	<detailed_description>The scientific investigation study protocol : 1 . Define role preemptive specific DLI preserving GVL effect set NMT . The ability select component T cell transplant DLI allow u test hypothesis distinctive role subset T cell . It find CD8-depleted DLI administer prevent relapse TCD ( T-cell deplete ) BMT ( bone marrow stem cell source ) CD34-selected PBSC . Whether preemptive CD8-depleted DLI perform function nonmyeloablative transplantation ( NMT ) need establish , propose study . If turns role DLI circumstance , CD8-depleted lymphocyte product limit GVHD would attractive option . We would also define relationship level donor chimerism disease control . 2 . Investigate impact CD8-depleted DLI NMT specific dos time point reduction GVHD . The GVHD pattern may vary different ethnic population suggest earlier NMT study . Our current propose study shed light optimal GVHD prophylaxis regimen Singapore patient population .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<criteria>1 . Confirmed diagnosis AML high risk MDS follow disease stage : Induction failure , first subsequent remission , untreated first relapse . 2 . Patient must HLAcompatible donor willing capable donate peripheral blood stem cell preferably bone marrow progenitor cell use conventional technique , lymphocyte indicate ( HLAcompatible define 5/6 6/6 match related 6/6 molecular match unrelated donor ) 3 . Both patient donor must sign write informed consent form . 4 . Patients must : ECOG PS &lt; /= 2 ; Ejective fraction &gt; 40 % ; DLCO &gt; 40 % predict ; Serum bilirubin &lt; /= 1.5x institutional upper limit normal ; SGPT ( ALT ) SGOT ( AST ) &lt; /= 2.5x institutional upper limit normal ; Serum creatinine &lt; /= 2x upper limit normal ; Creatinine clearance &gt; /= 60mL/min . However , renal dysfunction absolute contraindication NMT dialysis perform NMT . 1 . Not fulfil inclusion criterion 2 . Active lifethreatening infection 3 . Overt untreated infection 4 . HIV positivity , hepatitis B C antigen positivity active hepatitis 5 . Pregnant lactate woman 6 . Donor contraindication ( HIV seropositive confirm Western blot ; hepatitis B antigenemia ) 7 . Unable donate bone marrow peripheral blood due concurrent medical condition</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>High risk Myelodysplastic Syndrome ( MDS )</keyword>
</DOC>